Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome.
Infections in critically ill patients are a major burden to the healthcare system. Of concern for clinicians and administrators, neither the incidence of these infections over the past 30 years nor the mortality rates appear to be improving. This challenging dilemma has led to 70% of all intensive care unit (ICU) patients being prescribed antibiotics at any one time [1] . With such high rates of usage, it is easy to understand why the ICU stay is associated with the development of increasing levels of antibiotic-resistant bacteria that then pervade other healthcare settings.
For severe infections causing sepsis and septic shock, the early initiation of antibiotics with an appropriate spectrum for the likely pathogen has been demonstrated to be an effective intervention [2] [3] [4] . It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6] . These suggestions are based, in part, on numerous data demonstrating grossly altered pharmacokinetics in critically ill patients from small single-center studies [7] . Given that antibiotic dosing regimens are derived from healthy volunteers and do not account for these major differences in drug disposition, the present approach is likely to lead to suboptimal outcomes for critically ill patients [5, 8] .
The β-lactams ( penicillins, cephalosporins, carbapenems, and monobactams) are the most commonly prescribed family of antibiotics. From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial killing ( f T >MIC ) [9, 10] . Whereas animal in vivo studies have defined an f T >MIC between 40% and 70% of the dosing interval as being necessary [11] , retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13] . However, it remains unclear what PK/PD exposure is clinically necessary for maximal patient benefit.
With the present level of knowledge, there are few robust data to direct further improvement for antibiotic treatment in critically ill patients. Limiting progress is the absence of large-scale data on the appropriateness of present dosing. To address these deficiencies, we undertook the DALI (Defining Antibiotic Levels in Intensive Care Patients) study.
The primary objective of the study was to determine whether contemporary β-lactam antibiotic dosing in critically ill patients across a large number of ICUs achieves concentrations associated with maximal activity. The secondary objective was to correlate the observed antibiotic PK/PD with the clinical outcomes of therapy.
METHODS
The DALI study was a prospective, multicenter pharmacokinetic point-prevalence study. The detailed protocol for this study has been published previously [14] . The β-lactam antibiotics eligible for this analysis were amoxicillin (coadministered with clavulanate), ampicillin, cefazolin, cefepime, ceftriaxone, doripenem, meropenem, and piperacillin (coadministered with tazobactam).
Ethical approval to participate in this study was obtained at all participating centers and informed consent was obtained for each patient. The lead site was the University of Queensland, Australia (approval number 201100283, May 2011). Patients were all identified for participation by clinical ICU staff on the Monday of the nominated sampling week, with blood sampling and data collection occurring throughout that week.
PK/PD Targets
The PK/PD ratio is defined as the ratio between the measured free antibiotic concentration in plasma at 50% or 100% of the dosing interval and the MIC. The target PK/PD ratios used in this study are shown in Table 1 . Where available, the MIC of the known pathogen was provided by the local microbiology laboratory. Where an MIC was not available, as many centers do not routinely generate these data, the MIC of the pathogen was defined by the European Committee on Antimicrobial Susceptibility Testing's MIC 90 data (http://www.eucast.org/ clinical_breakpoints). Where no pathogen was formally identified, the highest MIC for susceptible bacteria to the antibiotic was assumed. These breakpoints were chosen for a worst-case scenario of bacterial susceptibility, which is what empiric dosing is based upon. 
Study Treatments and Blood Sampling
Antibiotic dosing was done as per the treating clinician and therapy could be administered by either intravenous intermittent or continuous infusion. Each patient had 2 blood samples taken for each β-lactam antibiotic he or she was receiving. Blood sample A was a mid-dose blood sample at 50% of the way through a dosing interval and blood sample B was a predose level at the end of a dosing interval. The observed concentrations were then interpreted in relation to the known or presumed MIC of the pathogen. For example, the 100% f T >4×MIC would be attained if the blood sample B concentration exceeded the MIC by at least a factor of 4.
Data Collection
Data collection was performed by trained staff at each participating center and entered onto a case report form. Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequential Organ Failure Assessment) score on day of sampling [16] . Mortality at 30 days was also collected. Clinical outcome of therapy was assessed using the definitions in Table 1 . Combination therapy was defined as the concomitant use of ≥2 antibiotics of different mechanistic classes at the time of pharmacokinetic sampling. Antibiotic dosing data including the dose, infusion duration, frequency of administration, the time of dosing and sampling, and the day of antibiotic therapy were collected. All data were collated by the coordinating center (Burns Trauma and Critical Care Research Centre, University of Queensland, Australia).
Maintenance of Sample Integrity
Blood samples were processed and stored per protocol to maintain integrity. A commercial courier company transported the clinical samples on dry ice to the coordinating center.
Bioanalysis
The concentration of the study antibiotics in the biological samples were determined by validated chromatographic methods (high performance liquid chromatography and liquid chromatography with tandem mass spectrometry) (US Food and Drug Administration guidelines: www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070107.pdf ). Unbound drug concentrations were directly measured for the highly protein-bound drugs cefazolin and ceftriaxone using ultrafiltration with 30 kDa cutoff devices (Centrifree, Merck Millipore, Tullagreen, Ireland) [17] .
Statistical Analysis
Basic statistics on demographic, clinical, and PK/PD-related data were presented by number (%) or median (interquartile range [IQR]), as appropriate. The distributions of clinical and PK/PD-related study parameters were compared among different antibiotics using the Kruskal-Wallis test.
To evaluate and compare the possible association of PK/PD targets with therapy-related outcome, after adjusting for APACHE II and SOFA scores, the skewed logistic regression technique was used [18] . The odds ratios (ORs) and bootstrapped 95% confidence intervals (CIs) were obtained, and the model fits were assessed using Akaike information criteria and Bayesian information criteria. Based on the estimated probabilities from the above models, the area under the receiver operating characteristic curve (AUROC) with 95% CIs was estimated.
The probability of a positive clinical outcome associated with the ratio of concentration to MIC in interaction with higher and lower levels of sickness severity (APACHE II score) were evaluated using an interaction-based logistic regression setup. High and low sickness severity groups were categorized into first and third quartiles. Graphical presentation of the confidence bounds for the probability of positive clinical outcome associated with concentration to MIC ratio were developed using these groups.
RESULTS

Demographic and Clinical Data
In 68 ICUs across 10 countries, 384 patients receiving β-lactam antibiotics were identified. Twenty-three patients were excluded because of protocol violations relating to incorrect blood sample timing, leaving 361 evaluable patients. The demographic and clinical details for the patients are described in Table 2 . Antibiotics were mostly used for treatment of infection (68.7%), with the remainder defined as therapy for prophylaxis of infection (31.3%). One-third of patients (32.6%) had their antibiotic course commenced in the 24 hours prior to blood sampling.
PK/PD Data
The data describing the achievement of PK/PD targets with empiric dosing are described in Table 3 . The box-and-whisker plots in Figure 1 show up to 500-fold variations in the unbound concentrations of some antibiotics at both the 50% and 100% sampling times. As shown by the boxplots in Figure 2 , this concentration variation also extended to variation of PK/PD indices at both time points.
Clinical Outcome Data
The clinical cure ( positive clinical outcome) rate across patients receiving both treatment and prophylaxis with β-lactam antibiotics was 66.5%. The most common indications for β-lactam therapy were lung infection (41%) and intra-abdominal infections (14%). By day 30 following study enrollment, 21.9% of patients had died; 40.8% of these deaths were considered to be related to the infection. The total infection-related mortality for all patients was 8.9%.
Among those treated for infection (n = 248), 144 (58.1%) patients had a positive clinical outcome. Of the patients treated for infection, 72.9% had a bacterial pathogen isolated, of which 34.2% had a pathogen MIC available. Of the pathogens identified, 18% were Pseudomonas aeruginosa (median MIC, 8 mg/L [IQR, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ) and 16% were Escherichia coli (median MIC, 4 mg/L [IQR 1-16]). The rates of positive clinical outcomes for these groups were 66% where no pathogen was isolated, 57% where 1 pathogen was isolated, and 54% for polymicrobial infections. β-Lactam monotherapy treatment was used in 38% of patients (n = 67), of whom 50% of patients achieved a positive clinical outcome (compared with the 63% in the combination therapy group).
Sixty-seven percent of patients being treated for infection received therapy by intermittent bolus dosing and 33% by prolonged infusion (either an extended infusion ≥2 hours or a continuous infusion). Of the patients who received prolonged infusion, 7% did not achieve 50% f T >MIC compared with 20% of patients receiving intermittent infusion.
Sixteen percent of patients treated for infection did not achieve 50% f T >MIC , and these patients were 32% less likely to have a positive clinical outcome (OR, 0.68 [95% CI,.52-.91]; P = .009).
In our multivariate regression models, only APACHE II score, SOFA score, and the PK/PD indices 50% f T >MIC and 100% f T >MIC were significantly associated with the clinical outcome (P < .05). The median APACHE II score for patients with The analyses of interaction effects of sickness severity status and increasing 50% f T >MIC ratios on the clinical outcome revealed that the likelihood of positive clinical outcome is significantly higher with increasing level of ratio of antibiotic concentration to MIC for those with lower APACHE II score, compared to those with higher APACHE II score ( Figure 3A and 3B) .
We also examined the effect of 50% f T >MIC on positive clinical outcome for different types of infection. For bloodstream infections (n = 24), a significant association was clearly present with increasing antibiotic concentrations at 50% of the dosing The pharmacokinetic/pharmacodynamic (PK/PD) ratios observed at 50% (A) and 100% (B) of the dosing interval. A ratio of 1 is considered to be a minimum PK/PD target of therapy at 50% of the dosing interval. Note that the PK/PD ratio is defined as the ratio between the measured antibiotic concentration in plasma at 50% or 100% of the dosing interval and the patient's minimum inhibitory concentration (MIC) or surrogate when MIC or pathogen is unknown. Abbreviation: f T >MIC , time the free (unbound) antibiotic concentration was maintained above the minimum inhibitory concentration. 
DISCUSSION
This multinational point prevalence study is the first to examine unbound plasma concentrations of β-lactam antibiotics and patient outcome across a large number of ICUs. These data show that mid-dose and trough β-lactam concentrations vary widely, and as such, achievement of PK/PD targets is highly inconsistent. Of great concern, one-fifth of patients do not even achieve a minimum conservative PK/PD target, 50% f T >MIC . This study has also generated interesting hypotheses related to much higher target β-lactam pharmacokinetic exposures than would have been previously considered for clinical outcome of infection. The dictum of "one dose fits all" is shown here to be problematic.
Our finding of large variations in plasma concentrations of β-lactam antibiotics in ICUs is in keeping with other studies. Recent reviews have noted the enormous pharmacokinetic variability of β-lactam antibiotics in critically ill patients [6, 7] ; however, all the studies commented on in these reviews were derived from single centers or from only very few related centers. Data are presented as estimates of odds ratios (95% CI) and P values. Abbreviations: AIC, Akaike information criteria; APACHE, Acute Physiology and Chronic Health Evaluation II; BIC, Bayesian information criteria; CI, confidence interval; f T >MIC , time the free (unbound) antibiotic concentration was maintained above the minimum inhibitory concentration; OR, odds ratio; SOFA, Sequential Organ Failure Assessment. Figure 3 . A, The effect of an increasing pharmacokinetic/pharmacodynamic (PK/PD) ratio at 50% of the dosing interval (ratio A) in interaction with Acute Physiology and Chronic Health Evaluation II (APACHE II) score on the probability of positive clinical outcome (n = 248; y-axis). B, The effect of PK/PD ratio at 50% of the dosing interval (ratio A) in interaction with APACHE II score on the probability of positive clinical outcome for patients not receiving renal replacement therapy (n = 220; y-axis). The estimated probabilities of positive clinical outcome along with its 95% confidence interval are presented for the less critically ill patient group (APACHE II score within lowest quartile of 0-14 points; solid black lines) as well as the more critically ill patient group (APACHE II score within the third quartile of 18-24 points; dashed line). Abbreviations: CI, confidence interval; MIC, minimum inhibitory concentration.
These studies are valuable because they demonstrate how antibiotic concentrations in different types of patients will differ from non-critically ill patients. Such data are essential for articulating how antibiotic dosing regimens that meet the specific needs of these patients could be developed given that present regimens are not tested in these most severely ill patients by pharmaceutical companies. Antibiotics discovered and evaluated in vitro are tested in animals initially for toxicity, and subsequently for efficacy. The antibiotic dose and frequency are based on these in vitro or animal in vivo PK/PD studies. These dosing regimens are then tested on healthy human volunteers for tolerability, with clinical efficacy studies undertaken in non-critically ill patients. After the launch of the drug onto the general market, the same dosing regimen is used in critically ill patients; however, this is likely to lead to suboptimal outcomes in the ICU. Critically ill patients have altered volumes of distribution for antibiotics [19, 20] , and, unlike other patient groups, need larger initial doses to rapidly achieve therapeutic concentrations [21] . These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23] . Critically ill patients often have low plasma albumin concentrations [24] that alters the protein binding of drugs and has significant effects on pharmacokinetics [25, 26] .
Given such potential for variability, it is not surprising that we found that one-fifth of patients did not achieve the most conservative PK/PD target and <50% of patients achieved what we a priori defined as a preferred PK/PD target (Table 3) . Furthermore, the variability of unbound concentrations across all antibiotics (Figure 1 ) as well as PK/PD ratios ( Figure 2) were similarly large.
The consequences of insufficient antibiotic exposure may be severe, with clear relationships being demonstrated between antibiotic underdosing and the development of antibiotic resistance [27] . This link was initially shown with inappropriately low quinolone exposures [28] , but more recently with other classes of antibiotics including β-lactams [29, 30] . ICUs are known to harbor multidrug-resistant pathogens and, although there are many reasons for this, optimized dosing that minimizes the evolution of such pathogens should be considered a method to improve patient and health system outcomes.
The secondary objective of this study was to compare antibiotic PK/PD with observed clinical outcomes. An interesting finding in our study is the observed significant interaction effect of varying sickness severity while evaluating the dose-response relationship. The patterns of probability of positive clinical outcome associated with increasing level of PK/PD ratio were markedly different for higher and lower levels of disease severity levels ( Figure 3 ). This novel analysis approach delineates the effect of antibiotic exposure more accurately. We found that the magnitude of the β-lactam exposures necessary to achieve a positive clinical outcome is particularly noteworthy and generates interesting research questions for future study.
The results of the DALI study support the conclusions of previous small studies that better outcomes for critically ill patients can be expected with higher drug exposures, at least for less severely ill patients [12, 13] . These data now support the conduct of an interventional study comparing critically ill patient outcomes with different PK/PD targets to definitively determine what antibiotic exposures should be targeted in these patients.
This study has notable limitations. While it is a prospectively designed point prevalence study, it is merely a snapshot picture of β-lactam antibiotic concentrations in critically ill patients on a single day [14] . Although we collected data on concomitant antibiotics, we did not assess the PK/PD of those antibiotics, nor did we assess duration of therapy of combination or monotherapy. Furthermore, pathogens were only grown in 73% of patients, and the actual MIC was only available in 34% of these patients, meaning that assumptions were necessary for the remaining patients. Such assumptions were of a worst-case scenario, which we believe is highly acceptable as this is the context governing empiric dose selection. If the infections were mediated by more susceptible bacteria than were assumed, the PK/PD ratios would actually have been higher than those we described here. Finally, we have not specifically looked at drug concentrations at the site of infection, because of the technical challenges in performing such a large-scale evaluation. However, our data interestingly show that for bloodstream infections, where antibiotic concentrations were measured, a strong PK/PD relationship was present.
CONCLUSIONS
The implications of this large study performed across 68 ICUs are profound. These data show that many patients fall below PK/PD targets (less than the most conservative PK/PD target in 20% of patients, and less than our suggested target in 50%). The results suggest that ICU clinicians should refine dosing strategies for critically ill patients to optimize β-lactam antibiotic outcomes. With the significant pharmacokinetic variability observed, a more personalized approach to antibiotic dosing would need to be adopted to ensure that target drug exposures are assured.
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